sera – Page 35 – Communicable Diseases Research

Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant

Article

Published on 2021-12-072022-10-28
Journal: Vaccines [Category] COVID-19,

Evaluation of different platforms for the detection of anti-SARS coronavirus-2 antibodies, Thailand

항 -SARS 코로나 바이러스 2 항체의 검출을위한 다른 플랫폼의 평가, 태국

Research

Published on 2021-12-062022-09-01
Journal: BMC Infectious Diseases [Category] SARS, 진단, 치료기술,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 analysed Analysis anti-SARS-CoV-2 anti-SARS-CoV-2 antibody antibodies antibody Antibody detection Architect assays Asymptomatic Chemiluminescence assay comparable coronavirus Coronavirus-2 country COVID-19 detect determine Disease diagnosis ELISA evaluated False-positive results feasibility four group four groups help IgG immunofluorescence assay immunological indirect immunofluorescence individuals Infection infection rate Laboratory large sample microneutralization Microneutralization assay Negative predictive value platform positive Positive predictive value Predictive value Prevalence respiratory Result risk SARS-coronavirus-2 SARS-CoV-2 SARS-CoV-2 antibodies sensitivity sera serum serum samples severe acute respiratory syndrome Coronavirus specificity symptomatic total Ig Vaccines
[DOI] 10.1186/s12879-021-06921-y PMC 바로가기 [Article Type] Research

Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination

델타의 중화 감소 (B.1.617.2) 예방 접종 후 SARS-COV-2 우려 변형

Research Article

Published on 2021-12-022022-08-13
Journal: PLoS Pathogens [Category] Biochemistry, SARS, 변종, 진단,

[키워드] (Beta accumulation African antibody Antibody titre antigenic antigenic drift antigenic profiles assessment Astra Zeneca Author B.1.351 B.1.617.1 B.1.617.2 bat bats Beta BNT162b2 BNT162b2 vaccines Booster vaccine booster vaccines ChAdOx1 changes in collected COVID-19 COVID19 death decrease decreases Delta delta variant dose effective Effectiveness Efficacy elicited evade expressed facilitate fold Fold changes glycoprotein groups hospitalisation Human human cell human cells humans Immunity India indicated individual Infection Lineage magnitude Mutation neutralisation neutralise Neutralising Antibodies neutralising antibody titres of BNT162b2 Pfizer Pfizer/BioNTech Prevent profile protective immune response pseudoviruses recipient recipients reduced reduction reduction in reductions reductions in required risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV-2 virus sensitivity sera Severe infection shape significantly higher South South Africa spike glycoprotein spike glycoproteins Spike protein subsequent the spike protein titre vaccinated individuals vaccination Vaccine vaccine efficacy Vaccines variant variant B.1.617.2 variants variants of concern Viral viral variant Viral variants virus Virus spike VOCs while with infection with infections Wuhan Wuhan, China
[DOI] 10.1371/journal.ppat.1010022 PMC 바로가기 [Article Type] Research Article

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1

HIV-1에 감염된 사람들에서 BNT162b2 mRNA COVID-19 백신의 면역원성과 안전성

Article

Published on 2021-12-012022-09-11
Journal: Clinical microbiology and infection : the official [Category] MERS, 진단, 치료제,

[키워드] 95% CI acute respiratory syndrome acute respiratory syndrome coronavirus Adverse adverse event adverse events AIDS anti-RBD Antiretroviral therapy appear BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine CD4 CD4 cell coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 vaccine disease enrolled event events fatigue geometric geometric mean HCWs headache health-care HIV-1 Human Human immunodeficiency virus IgG immune immunodeficiency immunodeficiency virus immunogenic immunogenicity injection injection site interquartile range median mRNA vaccine neutralized Neutralizing antibodies neutralizing antibody open Pain Patient Pfizer-BioNTech PLWH positive pseudo-virus RBD Receptor binding domain reported respiratory Safe SARS-CoV-2 second dose sera severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 suppressed T-cell vaccination Vaccine Viral Viral load were measured
[DOI] 10.1016/j.cmi.2021.07.031 PMC 바로가기 [Article Type] Article

Antigen production and development of an indirect ELISA based on the nucleocapsid protein to detect human SARS-CoV-2 seroconversion

인간 SARS-CoV-2 혈청전환을 검출하기 위한 뉴클레오캡시드 단백질에 기초한 간접 ELISA의 항원 생산 및 개발

Article

Published on 2021-12-012022-09-11
Journal: Brazilian journal of microbiology : [publication o [Category] MERS, 진단, 치료법,

Comirnaty-Elicited and Convalescent Sera Recognize Different Spike Epitopes

Article

Published on 2021-12-012022-10-28
Journal: Vaccines [Category] COVID-19,

Age-Dependent Reduction in Neutralization against Alpha and Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced Immunity

BNT162b2 SARS-CoV-2 백신 유도 면역의 알파 및 베타 변이체에 대한 중화의 연령 의존적 감소

Research Article

Published on 2021-12-012022-09-10
Journal: Microbiology Spectrum [Category] SARS, 변종, 진단,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 age All participants anti-RBD antibody antibody level antibody levels Antibody test Antigen basic Beta binding domain BNT162b2 BNT162b2 vaccine Clinical characteristics collected Coronavirus-2 correlated Cutoff decrease female groups Health care Health care worker health care workers heterogeneity high risk higher risk Humoral immunity Immunity include individual Infection interquartile range introduced IQR median mRNA vaccine mRNA vaccines neutralization Neutralizing Neutralizing activity Neutralizing antibodies of BNT162b2 Older age participant Patient patient age positive Pseudotyped virus questionnaire Questionnaires Randomly Receptor-binding domain reduction respiratory SARS-CoV-2 SARS-COV-2 infection second dose selected sera serum dilution Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus Spike protein Toyama U/mL university vaccination variant variants Viral viral variant Viral variants virus viruses was obtained were measured wild type wild-type wild-type SARS-CoV-2 wild-type virus
[DOI] 10.1128/Spectrum.00561-21 PMC 바로가기 [Article Type] Research Article

Microfluidic characterisation reveals broad range of SARS-CoV-2 antibody affinity in human plasma

미세 유체 특성 분석은 인간 혈장에서 광범위한 SARS-CoV-2 항체 친화성을 보여줍니다

Research Article

Published on 2021-11-302022-09-12
Journal: Life Science Alliance [Category] COVID19(2023년), MERS, SARS, 진단,

[키워드] affinity aggregate antibody antibody affinity Antibody Response antiviral antibodies antiviral antibody Asymptomatic cellular characterisation Clinical outcome complementary complexes Concentration COVID-19 infection Critically ill cytopathic determine dissociation domain effective healthy donors Human plasma indicate individual lethal magnitude mild symptoms neutralisation neutralisation assays neutralise plasma plasma sample plasma samples polyclonal polyclonal antibody predict receptor reveal SARS-CoV-2 antibody SARS-CoV-2 infections sera seropositive individual seropositive individuals significantly targets the antibody therapeutic Vaccinations virus
[DOI] 10.26508/lsa.202101270 PMC 바로가기 [Article Type] Research Article

The alpha/B.1.1.7 SARS-CoV-2 variant exhibits significantly higher affinity for ACE-2 and requires lower inoculation doses to cause disease in K18-hACE2 mice

alpha/B.1.1.7 SARS-CoV-2 변이체는 ACE-2에 대해 훨씬 더 높은 친화성을 나타내며 K18-hACE2 마우스에서 질병을 유발하기 위해 더 낮은 접종 용량이 필요합니다

Research Article

Published on 2021-11-252022-09-10
Journal: eLife [Category] MERS, SARS, 변종, 진단,

[키워드] a minor ACE-2 affinity Alpha angiotensin angiotensin-converting enzyme-2 anti-RBD Antibody neutralization asparagine B.1.1.7 B.1.1.7 variant convalescent individual convalescent individuals COVID-19 case disease Disease progression domination dose driven by elevated enzyme Epidemiology European exhibit faster functional hACE2 Human human Angiotensin-converting enzyme immunology incidence Infection K18-hACE2 mice low dose mice minor monoclonal antibodies mouse mouse model N501Y other variant other variants RBD Receptor-binding domain residue responsible SARS-CoV-2 SARS-CoV-2 lineage SARS-CoV-2 variant sera severity significantly higher Strains the receptor-binding domain transgenic transmission rate transmitted tyrosine United Kingdom variant Winter
[DOI] 10.7554/eLife.70002 PMC 바로가기 [Article Type] Research Article

Spike residue 403 affects binding of coronavirus spikes to human ACE2

Article

Published on 2021-11-252022-10-04
Journal: Nature Communications [Category] Fulltext, MERS, SARS, 변종, 조류인플루엔자,